@article{10.11648/j.ijcocr.20220703.15,
  author = {Stanislaw Rajmund Burzynski and Gregory Burzynski and Tomasz Janicki and Samuel Beenken},
  title = {Newly-Diagnosed Multicentric Pilocytic Astrocytoma: Complete Response and > 22 Years Survival in a Six Year and Nine-Month-Old Female Treated with Antineoplastons},
  journal = {International Journal of Clinical Oncology and Cancer Research},
  volume = {7},
  number = {3},
  pages = {76-82},
  doi = {10.11648/j.ijcocr.20220703.15},
  url = {https://doi.org/10.11648/j.ijcocr.20220703.15},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20220703.15},
  abstract = {Rationale: Pilocytic astrocytoma (PA) is generally a circumscribed, well-differentiated, slowly-growing tumor, classified as World Health Organization (WHO) grade I. The case of a female child with a newly diagnosed multicentric PA is presented here to detail and discuss the efficacy of Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal) in treatment of this disease. Objectives: The child was treated at the Burzynski Clinic (BC) according to the Phase II protocol, BT-23, which utilized Antineoplastons A10 and AS2-1 (ANP therapy) in the treatment of patients with optic pathway gliomas. ANP therapy was delivered via subclavian catheter and infusion pump. Tumor response was measured by sequential magnetic resonance imaging (MRI) of the brain. Findings: At presentation to the BC, the child complained of blurred vision and right-sided hemianopsia. On physical exam, she was alert and orientated. There was blurring of her right optic disc. Deep tendon reflexes were equal bilaterally with down-going toes. The child’s initial brain MRI and subsequent biopsy indicated a multi-centric PA involving the optic chiasm, hypothalamus and left hemisphere. Her parents elected for treatment at the BC. Baseline brain MRI, performed on November 15, 1999, showed three enhancing target lesions with a combined volume of 16.49 cm2. Sequential brain MRIs demonstrated that a partial response (PR) and then a complete response (CR) were achieved on April 12, 2000 and June 25, 2003, respectively. Twenty-two years after initiation of ANP therapy, the patient is doing well and showing no evidence of recurrent disease. Conclusions: The utilization of ANP therapy to obtain a cure of newly diagnosed multicentric PA in a female child is presented. We conclude that ANP therapy is an attractive therapeutic option for children with a multicentric PA or other PAs who are ineligible for or refuse standard therapy or demonstrate persistent, progressive, or recurrent disease following standard therapy.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Newly-Diagnosed Multicentric Pilocytic Astrocytoma: Complete Response and > 22 Years Survival in a Six Year and Nine-Month-Old Female Treated with Antineoplastons
AU  - Stanislaw Rajmund Burzynski
AU  - Gregory Burzynski
AU  - Tomasz Janicki
AU  - Samuel Beenken
Y1  - 2022/08/10
PY  - 2022
N1  - https://doi.org/10.11648/j.ijcocr.20220703.15
DO  - 10.11648/j.ijcocr.20220703.15
T2  - International Journal of Clinical Oncology and Cancer Research
JF  - International Journal of Clinical Oncology and Cancer Research
JO  - International Journal of Clinical Oncology and Cancer Research
SP  - 76
EP  - 82
PB  - Science Publishing Group
SN  - 2578-9511
UR  - https://doi.org/10.11648/j.ijcocr.20220703.15
AB  - Rationale: Pilocytic astrocytoma (PA) is generally a circumscribed, well-differentiated, slowly-growing tumor, classified as World Health Organization (WHO) grade I. The case of a female child with a newly diagnosed multicentric PA is presented here to detail and discuss the efficacy of Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal) in treatment of this disease. Objectives: The child was treated at the Burzynski Clinic (BC) according to the Phase II protocol, BT-23, which utilized Antineoplastons A10 and AS2-1 (ANP therapy) in the treatment of patients with optic pathway gliomas. ANP therapy was delivered via subclavian catheter and infusion pump. Tumor response was measured by sequential magnetic resonance imaging (MRI) of the brain. Findings: At presentation to the BC, the child complained of blurred vision and right-sided hemianopsia. On physical exam, she was alert and orientated. There was blurring of her right optic disc. Deep tendon reflexes were equal bilaterally with down-going toes. The child’s initial brain MRI and subsequent biopsy indicated a multi-centric PA involving the optic chiasm, hypothalamus and left hemisphere. Her parents elected for treatment at the BC. Baseline brain MRI, performed on November 15, 1999, showed three enhancing target lesions with a combined volume of 16.49 cm2. Sequential brain MRIs demonstrated that a partial response (PR) and then a complete response (CR) were achieved on April 12, 2000 and June 25, 2003, respectively. Twenty-two years after initiation of ANP therapy, the patient is doing well and showing no evidence of recurrent disease. Conclusions: The utilization of ANP therapy to obtain a cure of newly diagnosed multicentric PA in a female child is presented. We conclude that ANP therapy is an attractive therapeutic option for children with a multicentric PA or other PAs who are ineligible for or refuse standard therapy or demonstrate persistent, progressive, or recurrent disease following standard therapy.
VL  - 7
IS  - 3
ER  - 

Copy | Download